JPMorgan Chase & Co. Raises Stake in Accuray Incorporated (NASDAQ:ARAY)

JPMorgan Chase & Co. increased its stake in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 482.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 242,713 shares of the medical equipment provider's stock after acquiring an additional 201,037 shares during the quarter. JPMorgan Chase & Co. owned about 0.24% of Accuray worth $481,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ARAY. Virtu Financial LLC acquired a new stake in shares of Accuray during the third quarter worth about $244,000. Barclays PLC increased its position in Accuray by 97.9% during the third quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider's stock worth $380,000 after buying an additional 104,310 shares during the period. Assenagon Asset Management S.A. lifted its stake in Accuray by 28.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 212,330 shares of the medical equipment provider's stock valued at $420,000 after buying an additional 47,331 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Accuray by 2.1% in the third quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider's stock valued at $3,924,000 after acquiring an additional 45,548 shares during the period. Finally, Jane Street Group LLC grew its position in shares of Accuray by 26.1% during the third quarter. Jane Street Group LLC now owns 161,653 shares of the medical equipment provider's stock worth $291,000 after acquiring an additional 33,417 shares during the last quarter. 64.08% of the stock is owned by hedge funds and other institutional investors.

Accuray Stock Performance

Shares of NASDAQ ARAY traded up $0.02 during midday trading on Friday, reaching $1.37. 704,086 shares of the company were exchanged, compared to its average volume of 716,018. The stock has a market cap of $140.36 million, a P/E ratio of -27.30 and a beta of 1.30. Accuray Incorporated has a 1 year low of $1.34 and a 1 year high of $2.95. The stock has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $1.93. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51.

Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The business had revenue of $113.24 million during the quarter, compared to analysts' expectations of $101.53 million. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. On average, research analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Accuray from a "hold" rating to a "buy" rating in a research note on Friday, April 11th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.